- LOTTE Biologics has entered a contract development and manufacturing agreement with a U.S.-based oncology biotech company for antibody drug substance production.
- The work will be conducted at the Syracuse Bio Campus in New York, supporting late-stage clinical trials and process development for commercialization.
LOTTE Biologics has signed a contract development and manufacturing agreement with a U.S.-based biotechnology company focused on oncology, covering antibody drug substance production and process development for late-stage clinical programs.
Under the agreement, LOTTE Biologics will manufacture antibody drug substance for late-stage clinical trials and carry out process optimization at a commercial-ready scale. These activities will take place at the company’s Syracuse Bio Campus in New York.
The collaboration extends beyond clinical supply, supporting both late-stage development and potential future commercialization. The company stated that establishing a robust manufacturing process early is a key factor in the success of antibody therapeutics, and its infrastructure is designed to support programs through clinical and commercial stages.
LOTTE Biologics also highlighted its broader strategy to expand its CDMO and contract manufacturing capabilities through global partnerships. The Syracuse Bio Campus is positioned as a hub for late-stage projects, while integration with the Songdo Bio Campus, scheduled for mechanical completion this year, is expected to enhance end-to-end service offerings and supply chain management under a unified quality system.
“This contract represents an important step in building a foundation for large-scale global projects. We will continue to actively pursue additional opportunities to support clients through commercialization and beyond.”
LOTTE Biologics representative
